Vergelijking
Linaclotid vs. Oxytocin
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
851199-59-2
50-56-6
Molecuulmassa
1526.74 g/mol
1007.19 g/mol
Halfwaardetijd
geen gegevens
0.05 h
Sequentie
geen gegevens
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2Werkingsmechanisme
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Oxytocin
Oxytocin is synthesised in the hypothalamus and released via the posterior pituitary. Peripherally it binds the oxytocin receptor, a G-protein-coupled receptor, and through the phospholipase-C cascade and calcium release triggers contraction of uterine smooth muscle and milk ejection — the pharmacological basis of the obstetric approval. Centrally, oxytocin acts as a neuromodulator and has been linked to social bonding, trust and modulation of stress and anxiety circuits. Its central effects in humans are mechanistically incompletely understood, particularly because it is unclear to what extent peripherally or intranasally administered oxytocin crosses the blood-brain barrier.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
0
4
waarvan bij mensen
0
4
Geregistreerde effecten
2
3
Openstaande tegenstrijdigheden
0
1
Gedocumenteerde bijwerkingen
1
0
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Linaclotid and Oxytocin?
- Linaclotid is classified as "Onderzoek (overig)", while Oxytocin is classified as "Onderzoek (overig)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Oxytocin: Oxytocin is an endogenous nonapeptide hormone of the posterior pituitary. In synthetic form (Pitocin, Syntocinon) it has been approved for decades to induce and augment labour and to control postpartum uterine bleeding. Strictly separate from this is intranasal use to influence social behaviour, trust, anxiety or autism symptoms: this use is unapproved, purely experimental, and yields inconsistent and often negative results in controlled trials. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Linaclotid or Oxytocin?
- The highest available evidence level is "Humane RCT" for Linaclotid and "Humane RCT" for Oxytocin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Linaclotid and Oxytocin in Germany and the United States?
- Duitsland: Linaclotid — Op recept, Oxytocin — Op recept. Verenigde Staten: Linaclotid — Op recept, Oxytocin — Op recept. These are factual summaries with source and review date on the individual pages.